The Federal Circuit has called the BPCIA’s complicated biosimilar litigation process “a riddle wrapped inside a mystery inside an enigma.” The Supreme Court’s recent decision in Sandoz Inc. v. Amgen Inc. provides a modicum of clarity by ruling that the notice of commercial marketing required under the BPCIA from a biosimilar manufacturer may be provided before FDA approval of the biosimilar is obtained.
Uncertainty continues, however, regarding the BPCIA's information exchange. The Supreme Court concluded that an injunction is not available under the BPCIA to enforce disclosure of the abbreviated Biologics License Application and manufacturing information to the sponsor. But the Supreme Court determined that it was not necessary to decide under federal law whether such disclosure was mandatory or conditional. The Court remanded to the Federal Circuit the determination whether failure to follow the disclosure "requirement" of the BPCIA was "unlawful" under California unfair competition law and, if it was, whether state law injunctive relief was preempted by the BPCIA.
The panel will discuss the Supreme Court’s decision in Sandoz v. Amgen and factors for consideration going forward, including:
Moderator:
Cora R. Holt
Basil “Bill” J. Lewris
Linda A. Wadler
Wednesday, June 21, 2017
10:00 - 11:00 a.m. PDT
1:00 - 2:00 p.m. EDT
Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Conference
Boston Intellectual Property Law Association 4th Annual Symposium
April 10-11, 2024
Boston
Conference
Best Practices in Intellectual Property– A Decade of Dedication to IP Excellence
April 8-9, 2024
Tel Aviv
IAPP Global Privacy Summit 2024
April 3-4, 2024
Washington
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.